学科主题临床医学
Association of PIK3CA Mutation Status before and after Neoadjuvant Chemotherapy with Response to Chemotherapy in Women with Breast Cancer
Yuan, Hua1; Chen, Jiuan1; Liu, Yiqiang1; Ouyang, Tao1; Li, Jinfeng1; Wang, Tianfeng1; Fan, Zhaoqing1; Fan, Tie1; Lin, Benyao1; Xie, Yuntao1
刊名CLINICAL CANCER RESEARCH
2015-10-01
DOI10.1158/1078-0432.CCR-14-3354
21期:19页:4365-4372
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Oncology
资助者National Key Technology Research and Development Program of the Ministry of Science and Technology of China ; 973 project ; 985-III project ; National Natural Science Foundation of China ; National Key Technology Research and Development Program of the Ministry of Science and Technology of China ; 973 project ; 985-III project ; National Natural Science Foundation of China
研究领域[WOS]Oncology
关键词[WOS]FACTOR RECEPTOR 2 ; PHOSPHATIDYLINOSITOL 3-KINASE ; TENSIN HOMOLOG ; PTEN LOSS ; TRASTUZUMAB ; ACTIVATION ; PATHWAY ; GENE ; RESISTANCE ; PHOSPHATASE
英文摘要

Purpose: The association between PIK3CA mutations and response to neoadjuvant chemotherapy in women with primary breast cancer is not fully elucidated.

Experimental Design: PIK3CA mutations in breast cancer tissues that were taken prior to the initiation of neoadjuvant chemotherapy were identified in 729 operable primary breast cancer patients who received neoadjuvant chemotherapy. Among these, the PIK3CA mutations were also reassessed in tumor tissues procured following operation in 102 patients after completion of neoadjuvant chemotherapy.

Results: A total of 206 out of 729 (28.3%) patients had PIK3CA mutations, and 19.5% of patients (142/729) in this cohort achieved a pathologic complete response (pCR) after neoadjuvant chemotherapy. Patients with PIK3CA mutations exhibited a lower pCR rate than did those with wild-type (14.6% vs. 21.4%, P = 0.035). No significant differences in disease-free survival (DFS) or distant disease-free survival (DDFS) were observed between PIK3CA mutant and wild-type in the entire study population. Among the 102 patients with PIK3CA mutation statuses available before and after neoadjuvant chemotherapy, 24 patients (23.5%) had PIK3CA mutations before neoadjuvant chemotherapy. Of these 24 patients, 15 patients retained their initial PIK3CA mutations and 9 patients lost their initial mutations after neoadjuvant chemotherapy. Patients who retained the initial mutations after neoadjuvant chemotherapy (n = 15) had a worse DDFS than the remaining patients (n = 87) in this subgroup [unadjusted HR, 2.34; 95% confidence interval (CI), 0.98-5.62; P = 0.050].

Conclusions: Patients with PIK3CA mutations are less likely to respond to neoadjuvant chemotherapy. Patients who retain their initial PIK3CA mutations after neoadjuvant chemotherapy have an unfavorable survival. (C) 2015 AACR.

语种英语
所属项目编号2014BAI09B08 ; 2013CB911004 ; 30973436 ; 81071629
资助者National Key Technology Research and Development Program of the Ministry of Science and Technology of China ; 973 project ; 985-III project ; National Natural Science Foundation of China ; National Key Technology Research and Development Program of the Ministry of Science and Technology of China ; 973 project ; 985-III project ; National Natural Science Foundation of China
WOS记录号WOS:000363330500018
引用统计
被引频次:3[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/51281
专题北京大学临床肿瘤学院_乳腺癌预防治疗中心
作者单位1.Peking Univ Canc Hosp & Inst, Breast Ctr, Minist Educ, Key Lab Carcinogenesis & Translat Res, Beijing, Peoples R China
2.Peking Univ Canc Hosp & Inst, Dept Pathol, Beijing, Peoples R China
推荐引用方式
GB/T 7714
Yuan, Hua,Chen, Jiuan,Liu, Yiqiang,et al. Association of PIK3CA Mutation Status before and after Neoadjuvant Chemotherapy with Response to Chemotherapy in Women with Breast Cancer[J]. CLINICAL CANCER RESEARCH,2015,21(19):4365-4372.
APA Yuan, Hua.,Chen, Jiuan.,Liu, Yiqiang.,Ouyang, Tao.,Li, Jinfeng.,...&Xie, Yuntao.(2015).Association of PIK3CA Mutation Status before and after Neoadjuvant Chemotherapy with Response to Chemotherapy in Women with Breast Cancer.CLINICAL CANCER RESEARCH,21(19),4365-4372.
MLA Yuan, Hua,et al."Association of PIK3CA Mutation Status before and after Neoadjuvant Chemotherapy with Response to Chemotherapy in Women with Breast Cancer".CLINICAL CANCER RESEARCH 21.19(2015):4365-4372.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Yuan, Hua]的文章
[Chen, Jiuan]的文章
[Liu, Yiqiang]的文章
百度学术
百度学术中相似的文章
[Yuan, Hua]的文章
[Chen, Jiuan]的文章
[Liu, Yiqiang]的文章
必应学术
必应学术中相似的文章
[Yuan, Hua]的文章
[Chen, Jiuan]的文章
[Liu, Yiqiang]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。